产品名称

ARQ 197 - Tivantinib

产品货号

Axon 1838 CAS [905854-02-6] MF C23H19N3O2MW 369.42 Purity: 98% Soluble in DMSO Description Selective, non-ATP-competitive and orally bioavailable inhibitor of c-MET receptor tyrosine kinase (RTK) References Certificates Categories Extra info N Munshi et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity. Mol. Cancer Ther. 2010, 9, 1544-1553. R Bagai et al. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010, 13(6), 404-414. AA Adjei et al. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist. 2011, 16(6), 788-799. S Eathiraj et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation (...). J. Biol. Chem. 2011, 286(23), 20666-20676. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology c-MET RTK class X; EC 2.7.10.1 c-MET tyrosine kinase Inhibitor Chemical name (3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione Parent CAS No. [905854-02-6] Order Size Unit Price Stock 5 mg €95.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

ARQ 197 - Tivantinib

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1838

CAS [905854-02-6]

MF C23H19N3O2
MW 369.42

Purity: 98%
Soluble in DMSO

ARQ 197

Description

Selective, non-ATP-competitive and orally bioavailable inhibitor of c-MET receptor tyrosine kinase (RTK)

N Munshi et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity. Mol. Cancer Ther. 2010, 9, 1544-1553.

R Bagai et al. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010, 13(6), 404-414.

AA Adjei et al. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist. 2011, 16(6), 788-799.

S Eathiraj et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation (...). J. Biol. Chem. 2011, 286(23), 20666-20676.

Cell Signaling & Oncology c-MET RTK class X; EC 2.7.10.1

c-MET tyrosine kinase Inhibitor

Chemical name

(3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione

Parent CAS No.

[905854-02-6]

产品资料